Peptide-containing composition for inhibiting hair loss or promoting hair growth

Abstract

The present disclosure relates to the use of a specific peptide for preparing a composition for inhibiting hair loss or promoting hair growth. Specifically, the composition disclosed by the invention can effectively inhibit alopecia or promote hair growth by promoting or activating growth or proliferation of hair papilla cells.

Description

TECHNICAL FIELD

[0001] The present disclosure relates to a composition for inhibiting hair loss or promoting hair growth containing a specific peptide. BACKGROUND

[0002] Human hair is primarily responsible for the defense function of protecting the scalp from external stimulating factors such as ultraviolet rays, and the aesthetic function of expressing the individual's external image. However, in modern society, due to natural factors such as environmental pollution and strong ultraviolet rays, physiological factors such as stress and hormonal imbalance, hair loss frequently occurs, and unlike the past, which was limited to adult males, hair loss occurs regardless of age, gender, and age, and thus there is an urgent need for a material for preventing and treating hair loss.

[0003] The hair follicle, which is a physiological organ in the body that produces hair, repeatedly undergoes a hair cycle including a growth phase in which hair is formed and the formed hair actively grows, a catagen phase in which hair degenerates, a telogen phase in which hair is maintained until it falls out, and an exogen phase in which hair loss occurs, during the development process after birth and participates in the growth, maintenance, and shedding of hair. It has been found through many studies that the activity of the hair follicle is caused by hair dermal papilla cells, and in particular, the proliferation and differentiation of hair dermal papilla cells first participate in the progress of the hair cycle and hair formation. In the growth phase in which hair actively grows, hair dermal papilla cells actively undergo active proliferation and differentiation, whereas in the catagen phase, telogen phase, and exogen phase in which hair growth stops and hair loss occurs, these cells undergo apoptosis. Therefore, hair growth and hair loss are closely related to the proliferation and apoptosis of hair dermal papilla cells, and by inducing the proliferation of hair dermal papilla cells to extend the growth phase or inhibit cell apoptosis and shorten the catagen phase, telogen phase, and exogen phase, it is possible to improve and treat hair loss.

[0004] Alopecia refers to a symptom in which more than 100 hairs are lost per day, the number of hairs in a growth phase is reduced, and the number of hairs in a resting phase or telogen phase is increased, and as alopecia progresses, the proportion of hairs in the resting phase is sharply increased, and in correspondence thereto, the proportion of hairs in the growth phase is reduced. In general, alopecia can be classified into genetic androgenetic alopecia (baldness), alopecia areata, tinea capitis caused by fungal infection, telogen effluvium, trichotillomania, and hair loss diseases. Among them, the most common alopecias are baldness (male pattern baldness), female pattern baldness, alopecia areata, and telogen effluvium. The causes of alopecia are various. In the occurrence of baldness, genetic factors and androgens, which are male hormones, are considered to be important factors, and in female pattern baldness, it is also believed that some of them occur through the same route as male pattern baldness, but the clinical manifestations thereof are different. Alopecia areata is believed to be caused by an autoimmune disease. Telogen effluvium is temporary hair loss that occurs after severe physical or mental stress such as endocrine diseases, malnutrition, drugs, childbirth, fever, surgery, etc., and some of the hairs fail to complete the growth phase and enter the resting phase, thereby being lost. SUMMARY

[0005] Technical Problem

[0006] The present disclosure aims to provide a composition that exhibits excellent hair loss inhibiting or hair growth promoting effects by promoting or activating the growth or proliferation of hair papilla cells.

[0007] Means for Solving the Problem

[0008] To achieve the object, according to an embodiment of the present disclosure, there is provided a use of a peptide including an amino acid sequence of Gly-Pro-Lys (GPK), an amino acid sequence of Gly-Pro-Ser (GPS), an amino acid sequence of Gly-Pro-Ala (GPA), an amino acid sequence of Gly-Gln-Lys (GQK), or an amino acid sequence of Pro-Hyp (PO); or a salt thereof, for preparing a composition for inhibiting hair loss or promoting hair growth.

[0009] Effects of the Invention

[0010] The composition according to the present disclosure can effectively inhibit hair loss or promote hair growth by promoting or activating the growth or proliferation of hair papilla cells. BRIEF DESCRIPTION OF DRAWINGS

[0011] Figure 1 Results confirming the effect of GPK peptide on activating the proliferation of hair papilla cells are shown.

[0012] Figure 2 Results confirming the effect of GPS peptide on activating the proliferation of hair papilla cells are shown.

[0013] Figure 3Results showing confirmation of the effect of GQK peptide on activation of hair papilla cell proliferation.

[0014] Figure 4 Results showing confirmation of the effect of GQK peptide on activation of hair papilla cell proliferation.

[0015] Figure 5 Results showing confirmation of the effect of PO peptide on activation of hair papilla cell proliferation. DETAILED DESCRIPTION

[0016] Hereinafter, the present application will be described in detail.

[0017] In one aspect, the present application can relate to a use of a peptide including a Gly-Pro-Lys amino acid sequence (GPK) or a salt thereof for preparing a composition for inhibiting hair loss or promoting hair growth.

[0018] In one aspect, the present application can relate to a use of a peptide including a Gly-Pro-Ser amino acid sequence (GPS) or a salt thereof for preparing a composition for inhibiting hair loss or promoting hair growth.

[0019] In one aspect, the present application can relate to a use of a peptide including a Gly-Pro-Ala amino acid sequence (GPA) or a salt thereof for preparing a composition for inhibiting hair loss or promoting hair growth.

[0020] In one aspect, the present application can relate to a use of a peptide including a Gly-Gln-Lys amino acid sequence (GQK) or a salt thereof for preparing a composition for inhibiting hair loss or promoting hair growth.

[0021] In one aspect, the present application can relate to a use of a peptide including a Pro-Hyp amino acid sequence (PO) or a salt thereof for preparing a composition for inhibiting hair loss or promoting hair growth.

[0022] In one aspect, the present application can relate to a use of a peptide including a Gly-Pro-Thr amino acid sequence (GPT) or a salt thereof for preparing a composition for inhibiting hair loss or promoting hair growth.

[0023] In one aspect, the present application can relate to a use of a peptide including a Arg-Lys amino acid sequence (RK) or a salt thereof for preparing a composition for inhibiting hair loss or promoting hair growth.

[0024] In one aspect, the present application can relate to a use of a peptide including a Pro-Gly-Glu amino acid sequence (PGE) or a salt thereof for preparing a composition for inhibiting hair loss or promoting hair growth.

[0025] In one aspect, the present application can relate to a composition for inhibiting hair loss or promoting hair growth, containing a peptide including a Gly-Pro-Lys amino acid sequence (GPK) or a salt thereof as an effective ingredient.

[0026] In one aspect, the present application can relate to a composition for inhibiting hair loss or promoting hair growth, containing a peptide including a Gly-Pro-Ser amino acid sequence (GPS) or a salt thereof as an effective ingredient.

[0027] In one aspect, the present application can relate to a composition for inhibiting hair loss or promoting hair growth, containing a peptide including a Gly-Pro-Ala amino acid sequence (GPA) or a salt thereof as an effective ingredient.

[0028] In one aspect, the present application can relate to a composition for inhibiting hair loss or promoting hair growth, containing a peptide including a Gly-Gln-Lys amino acid sequence (GQK) or a salt thereof as an effective ingredient.

[0029] In one aspect, the present application can relate to a composition for inhibiting hair loss or promoting hair growth, containing a peptide including a Pro-Hyp amino acid sequence (PO) or a salt thereof as an effective ingredient.

[0030] In one aspect, the present application can relate to a composition for inhibiting hair loss or promoting hair growth, containing a peptide including a Gly-Pro-Thr amino acid sequence (GPT) or a salt thereof as an effective ingredient.

[0031] In one aspect, the present application can relate to a composition for inhibiting hair loss or promoting hair growth, containing a peptide including a Arg-Lys amino acid sequence (RK) or a salt thereof as an effective ingredient.

[0032] In one aspect, the present application can relate to a composition for inhibiting hair loss or promoting hair growth, containing a peptide including a Pro-Gly-Glu amino acid sequence (PGE) or a salt thereof as an effective ingredient.

[0033] In the present specification, the amino acids referred to using abbreviations are as shown below, and are described according to the IUPAC-IUB nomenclature:

[0034] Glycine: G, Proline: P, Lysine: K, Serine: S, Alanine: A, Glutamine: Q, Hydroxyproline: O, Threonine: T, Arginine: R, Glutamic acid: E

[0035] In one embodiment, the peptide can be the GPK, GPS, GPA, GQK, PO, GPT, RK, or PGE amino acid in a ratio of 50% or more, 60% or more, 70% or more, 80% or more, or 90% or more, can preferably be 95% or more, and most preferably be 100%.

[0036] In one embodiment, the peptide can be a GPK, GPS, GPA, GQK, PO, GPT, RK, or PGE peptide. That is, the peptide can be a peptide consisting of the amino acid sequence of Gly-Pro-Lys, the amino acid sequence of Gly-Pro-Ser, the amino acid sequence of Gly-Pro-Ala, the amino acid sequence of Gly-Gln-Lys, the amino acid sequence of Pro-Hyp, the amino acid sequence of Gly-Pro-Thr, the amino acid sequence of Arg-Lys, or the amino acid sequence of Pro-Gly-Glu.

[0037] In the present specification, even if described as "a peptide consisting of a specific amino acid sequence", as long as having the same or corresponding activity to a peptide consisting of the amino acid sequence, the addition of meaningless sequences before and after the amino acid sequence or mutations or potential mutations that can occur naturally are not excluded, and even if having such sequence addition or mutation, it is obviously within the scope of the present application.

[0038] In one embodiment, the peptide can be prepared by a chemical synthesis method known in the art, a standard synthesis method, a protein decomposition method by an enzyme or base or acid, or any other method in the art.

[0039] In the present specification, the "peptide salt" can be a pharmaceutically or cosmetically acceptable salt. Specifically, the peptide salt can be formed by adding an acid to a peptide, for example, can be formed by adding an inorganic acid (such as hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, etc.), an organic carboxylic acid (such as acetic acid, halogenated acetic acid such as trifluoroacetic acid, propionic acid, maleic acid, succinic acid, malic acid, citric acid, tartaric acid, salicylic acid), and an acidic sugar (glucuronic acid, galacturonic acid, gluconic acid, ascorbic acid), an acidic polysaccharide (such as hyaluronic acid, chondroitin sulfate, alginic acid), an organic sulfonic acid containing a chondroitin sulfate such as methanesulfonic acid, p-toluenesulfonic acid, etc.

[0040] In one embodiment, the peptide or salt thereof can be contained in the composition at a concentration of 0.001 to 200 μM.

[0041] For example, the concentration of the peptide or salt thereof in the composition can be 0.001 μM or more, 0.005 μM or more, 0.01 μM or more, 0.05 μM or more, 0.1 μM or more, 0.5 μM or more, 1 μM or more, 5 μM or more, 10 μM or more, 15 μM or more, 20 μM or more, 25 μM or more, 30 μM or more, 35 μM or more, 40 μM or more, 45 μM or more, 50 μM or more, 55 μM or more, 60 μM or more, 65 μM or more, 70 μM or more, 75 μM or more, 80 μM or more, 85 μM or more, 90 μM or more, 95 μM or more, 100 μM or more, 110 μM or more, 120 μM or more, 130 μM or more, 140 μM or more, 150 μM or more, 160 μM or more, 170 μM or more, 180 μM or more, or 190 μM or more, and in addition, the concentration of the peptide or salt thereof in the composition can be 200 μM or less, 190 μM or less, 180 μM or less, 170 μM or less, 160 μM or less, 150 μM or less, 140 μM or less, 130 μM or less, 120 μM or less, 110 μM or less, 100 μM or less, 95 μM or less, 90 μM or less, 85 μM or less, 80 μM or less, 75 μM or less, 70 μM or less, 65 μM or less, 60 μM or less, 55 μM or less, 50 μM or less, 45 μM or less, 40 μM or less, 35 μM or less, 30 μM or less, 25 μM or less, 20 μM or less, 15 μM or less, 10 μM or less, 5 μM or less, 1 μM or less, 0.5 μM or less, 0.1 μM or less, 0.05 μM or less, 0.01 μM or less, or 0.005 μM or less.

[0042] In one embodiment, the peptide or salt thereof can be treated to the cells at a concentration of 0.1 to 10 μM.

[0043] For example, the peptide or salt thereof can be treated to the cells at a concentration of 0.1 μM or more, 0.2 μM or more, 0.3 μM or more, 0.4 μM or more, 0.5 μM or more, 0.6 μM or more, 0.7 μM or more, 0.8 μM or more, 0.9 μM or more, 1 μM or more, 2 μM or more, 3 μM or more, 4 μM or more, 5 μM or more, 6 μM or more, 7 μM or more, 8 μM or more, or 9 μM or more, and in addition, the peptide or salt thereof can be treated to the cells at a concentration of 10 μM or less, 9 μM or less, 8 μM or less, 7 μM or less, 6 μM or less, 5 μM or less, 4 μM or less, 3 μM or less, 2 μM or less, 1 μM or less, 0.9 μM or less, 0.8 μM or less, 0.7 μM or less, 0.6 μM or less, 0.5 μM or less, 0.4 μM or less, 0.3 μM or less, or 0.2 μM or less.

[0044] In an embodiment, the cell can be a hair papilla cell.

[0045] In an embodiment, the peptide or salt thereof can promote or activate growth or proliferation of a hair papilla cell.

[0046] In an embodiment, the composition can be a pharmaceutical composition for preventing or treating alopecia.

[0047] In the present specification, "prevention" means reducing the risk of a disease or disorder, and means all actions that prevent one or more clinical symptoms of a disease from further developing, thereby inhibiting or delaying the onset of a disease, in a subject exposed to a disease or susceptible to a disease but not yet suffering from a disease or showing symptoms of a disease.

[0048] In the present specification, "treatment" means alleviating a disease or disorder, and includes all actions that prevent or reduce the further development of a disease or one or more clinical symptoms of a disease, thereby improving or changing in a beneficial direction the symptoms of a disease.

[0049] In one embodiment, the amount of the peptide or salt thereof to be administered per day can be 0.0002 to 100 mg / kg (body weight). Specifically, the amount of the peptide or salt thereof to be administered per day can be 0.0002 mg / kg (body weight) or more, 0.0003 mg / kg (body weight) or more, 0.0005 mg / kg (body weight) or more, 0.0007 mg / kg (body weight) or more, 0.001 mg / kg (body weight) or more, 0.005 mg / kg (body weight) or more, 0.01 mg / kg (body weight) or more, 0.03 mg / kg (body weight) or more, 0.05 mg / kg (body weight) or more, 0.07 mg / kg (body weight) or more, 0.08 mg / kg (body weight) or more, 0.1 mg / kg (body weight) or more, 0.5 mg / kg (body weight) or more, 1 mg / kg (body weight) or more, 5 mg / kg (body weight) or more, 10 mg / kg (body weight) or more, 15 mg / kg (body weight) or more, 20 mg / kg (body weight) or more, 25 mg / kg (body weight) or more, 30 mg / kg (body weight) or more, 35 mg / kg (body weight) or more, 40 mg / kg (body weight) or more, 45 mg / kg (body weight) or more, 50 mg / kg (body weight) or more, 60 mg / kg (body weight) or more, 70 mg / kg (body weight) or more, 80 mg / kg (body weight) or more, or 90 mg / kg (body weight) or more, and in addition, the amount of the peptide or salt thereof to be administered per day can be 100 mg / kg (body weight) or less, 90 mg / kg (body weight) or less, 80 mg / kg (body weight) or less, 60 mg / kg (body weight) or less, 50 mg / kg (body weight) or less, 45 mg / kg (body weight) or less, 40 mg / kg (body weight) or less, 35 mg / kg (body weight) or less, 30 mg / kg (body weight) or less, 25 mg / kg (body weight) or less, 20 mg / kg (body weight) or less, 15 mg / kg (body weight) or less, 10 mg / kg (body weight) or less, 5 mg / kg (body weight) or less, 1 mg / kg (body weight) or less, 0.9 mg / kg (body weight) or less, 0.5 mg / kg (body weight) or less, 0.1 mg / kg (body weight) or less, 0.07 mg / kg (body weight) or less, 0.05 mg / kg (body weight) or less, 0.03 mg / kg (body weight) or less, 0.01 mg / kg (body weight) or less, 0.005 mg / kg (body weight) or less, 0.001 mg / kg (body weight) or less, 0.0007 mg / kg (body weight) or less, or 0.0005 mg / kg (body weight) or less.

[0050] In one embodiment, the peptide or salt thereof can be contained in the pharmaceutical composition in a therapeutically effective amount, and a pharmaceutically acceptable carrier can also be included. The term "therapeutically effective amount" means an amount sufficient to achieve the prevention or treatment of alopecia as an object of the present composition.

[0051] In the present specification, alopecia refers to the absence of hair in a portion where hair is normally present, including a phenomenon in which the amount of hair is less than that in a normal state. The alopecia includes the concept of both non-scarring alopecia and scarring alopecia according to whether hair follicles are destroyed, for example, including all of androgenic alopecia due to heredity, alopecia areata, tinea capitis due to fungal infection, telogen effluvium, trichotillomania, alopecia due to a hair growth disorder disease, or alopecia due to lupus, kerion, alopecia due to burn and / or trauma, and the like.

[0052] The prevention or treatment of the alopecia can be to eliminate the cause of the alopecia as described above or to inhibit the progress of the alopecia, and can inhibit hair loss or promote hair growth to promote hair growth.

[0053] In an embodiment, the pharmaceutical composition can be prepared by formulating the peptide or salt thereof using a pharmaceutically acceptable carrier and / or excipient by a method easily performed by those skilled in the art, in a unit capacity form or contained in a multi-capacity container. At this time, the formulation can be in the form of a solution, suspension, or emulsion in an oily or aqueous medium, or can also be in the form of an extract, powder, granule, tablet, capsule, or gel (e.g., hydrogel), and can further include a dispersant or stabilizer.

[0054] In an embodiment, the peptide or salt thereof contained in the pharmaceutical composition can be delivered by a pharmaceutically acceptable carrier such as a colloidal suspension, powder, physiological saline, lipid, liposome, microspheres, or nanospheric particles. They can form a complex or be associated with a delivery medium, and can be delivered in vivo using a delivery system known in the art such as a lipid, liposome, microparticle, gold, nanoparticle, polymer, condensing agent, polysaccharide, polyamino acid, dendrimer, saponin, adsorption enhancer, or fatty acid.

[0055] In addition, the pharmaceutically acceptable carrier can include lactose, glucose, sucrose, sorbitol, mannitol, starch, gum arabic, rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, sugar syrup, methyl cellulose, methyl paraben, propyl paraben, talc, magnesium stearate, and mineral oil, etc., which are commonly used in formulations, but is not limited thereto. In addition, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc. can be further included in addition to the ingredients.

[0056] In an embodiment, the pharmaceutical composition can be administered orally or non-orally, and can be used in the form of a conventional pharmaceutical preparation. That is, the pharmaceutical composition of the present application can be administered in various dosage forms for oral and non-oral administration, and when formulated, a diluent or an excipient such as a common filler, a bulking agent, a binding agent, a wetting agent, a disintegrating agent, a surfactant, etc. is used for the preparation. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations are prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. with the crude drug extract or the crude drug fermentate. In addition, a lubricant such as magnesium stearate, talc, etc. is used in addition to the simple excipient. As liquid preparations for oral administration, suspensions, internal liquids, emulsions, syrup, etc. are included, and in addition to water, liquid paraffin, which is a common simple diluent, various excipients such as a wetting agent, a sweetener, an aromatic, a preservative, etc. can be included. Preparations for non-oral administration include a sterilized aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a lyophilized preparation, a suppository. As the non-aqueous solvent, a suspension solvent, injectable esters such as propylene glycol, polyethylene glycol, vegetable oils such as olive oil, ethyl oleate, etc. can be used. As a base for a suppository, vitamin E, polyethylene glycol, Tween 61, cocoa butter, trilaurin, glycerin, gelatin, etc. can be used.

[0057] In an embodiment, the pharmaceutical composition can be a skin external agent. The skin external agent is a preparation in the form of an agent that can be applied to the outside of the skin, and when the pharmaceutical composition of the present application is used as a skin external agent, it can be applied to the scalp, particularly the scalp at a site where alopecia occurs or a site where hair growth is desired. The skin external agent can be a cream, a gel, an ointment, a skin emulsion, a skin suspension, a transdermal patch, a medicated bandage, a lotion, or a combination thereof. The skin external agent can be appropriately formulated using ingredients commonly used in skin external agents such as cosmetics or pharmaceuticals, such as an aqueous ingredient, an oily ingredient, a powder ingredient, an alcohol, a humectant, a thickening agent, an ultraviolet absorber, a whitening agent, a preservative, an antioxidant, a surfactant, a perfume, a pigment, various skin nutrients, or a combination thereof, as needed. The skin external agent can also be appropriately formulated using a metal blocking agent such as disodium ethylenediaminetetraacetate, trisodium ethylenediaminetetraacetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, gluconic acid, etc., an agent such as caffeine, tannin, verapamil, licorice extract, glabridin, hot water extract of Calin fruit, various crude drugs, tocopherol acetate, glycyrrhizic acid, tranexamic acid and derivatives thereof or salts thereof, etc., a sugar such as vitamin C, ascorbic acid magnesium phosphate, ascorbic acid glucoside, arbutin, kojic acid, glucose, fructose, trehalose, etc.

[0058] In an embodiment, the composition can be a cosmetic composition.

[0059] In one embodiment, the amount of the peptide or salt thereof to be administered per day can be 0.0002 to 100 mg / kg (body weight). Specifically, the amount of the peptide or salt thereof to be administered per day can be 0.0002 mg / kg (body weight) or more, 0.0003 mg / kg (body weight) or more, 0.0005 mg / kg (body weight) or more, 0.0007 mg / kg (body weight) or more, 0.001 mg / kg (body weight) or more, 0.005 mg / kg (body weight) or more, 0.01 mg / kg (body weight) or more, 0.03 mg / kg (body weight) or more, 0.05 mg / kg (body weight) or more, 0.07 mg / kg (body weight) or more, 0.08 mg / kg (body weight) or more, 0.1 mg / kg (body weight) or more, 0.5 mg / kg (body weight) or more, 1 mg / kg (body weight) or more, 5 mg / kg (body weight) or more, 10 mg / kg (body weight) or more, 15 mg / kg (body weight) or more, 20 mg / kg (body weight) or more, 25 mg / kg (body weight) or more, 30 mg / kg (body weight) or more, 35 mg / kg (body weight) or more, 40 mg / kg (body weight) or more, 45 mg / kg (body weight) or more, 50 mg / kg (body weight) or more, 60 mg / kg (body weight) or more, 70 mg / kg (body weight) or more, 80 mg / kg (body weight) or more, or 90 mg / kg (body weight) or more, and in addition, the amount of the peptide or salt thereof to be administered per day can be 100 mg / kg (body weight) or less, 90 mg / kg (body weight) or less, 80 mg / kg (body weight) or less, 60 mg / kg (body weight) or less, 50 mg / kg (body weight) or less, 45 mg / kg (body weight) or less, 40 mg / kg (body weight) or less, 35 mg / kg (body weight) or less, 30 mg / kg (body weight) or less, 25 mg / kg (body weight) or less, 20 mg / kg (body weight) or less, 15 mg / kg (body weight) or less, 10 mg / kg (body weight) or less, 5 mg / kg (body weight) or less, 1 mg / kg (body weight) or less, 0.9 mg / kg (body weight) or less, 0.5 mg / kg (body weight) or less, 0.1 mg / kg (body weight) or less, 0.07 mg / kg (body weight) or less, 0.05 mg / kg (body weight) or less, 0.03 mg / kg (body weight) or less, 0.01 mg / kg (body weight) or less, 0.005 mg / kg (body weight) or less, 0.001 mg / kg (body weight) or less, 0.0007 mg / kg (body weight) or less, or 0.0005 mg / kg (body weight) or less.

[0060] In one embodiment, the cosmetic composition can include a cosmetically effective amount of the peptide or salt thereof, which is an amount sufficient to achieve the aforementioned hair loss prevention or hair growth promotion effect, and a cosmetically acceptable carrier.

[0061] In one embodiment, the cosmetic composition can further contain other ingredients having characteristics capable of synergistically acting on the activity of the peptide within a range not affecting the hair loss prevention or hair growth promotion activity of the peptide. For example, it can contain a fatty substance, an organic solvent, a dissolving agent, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, an ionic or non-ionic emulsifier, a filler, a metal ion blocking and chelating agent, a preservative, a vitamin, a blocking agent, a humectant, a base oil, a dye, a pigment, a perfume, a hydrophilic or lipophilic active agent, a liposome, or any other ingredient conventionally used in the cosmetic or dermatological field, and the like, and the ingredients can be contained in amounts conventionally used in the cosmetic or dermatological field.

[0062] In one embodiment, the cosmetic composition can be a hair care nutrient, a hair rinse, a hair serum, a hair cream, a hair care nutrient cream, a shampoo, a hair conditioner, a hair rinse, a hair cream, a hair care nutrient cream, a hair care moisturizing cream, a hair care massage cream, a hair wax, a hair care aerosol, a hair pack, a hair care nutrient pack, a hair soap, a hair cleansing foam, a hair oil, a hair drying agent, a hair preservation treatment agent, a hair dye, a hair waving agent, a hair bleaching agent, a hair gel, a hair lacquer, a hair styling agent, a hair stick agent, a hair moisturizing agent, a hair mousse, a hair care spray, an eyebrow growth agent, a mascara growth agent, a mascara nutrient agent.

[0063] In one embodiment, the cosmetic composition can be manufactured in any dosage form conventionally manufactured in the art, for example, can be formulated as a solution, a suspension, an emulsion, a paste, a powder, a gel, a cream, a lotion, a soap, an oil, a spray, and the like, but is not limited thereto.

[0064] When the dosage form of the cosmetic composition is a paste, a cream, or a gel, an animal oil, a vegetable oil, a wax, a paraffin, a starch, a xanthan gum, a cellulose derivative, a polyethylene glycol, a silica gel, a bentonite, a silica, a talc, or a zinc oxide, and the like can be used as a carrier ingredient.

[0065] When the dosage form of the cosmetic composition is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or a polyamide powder can be used as a carrier ingredient, and particularly when it is a spray, a propellant such as a chlorofluorocarbon, propane / butane, or dimethyl ether, and the like can be further contained.

[0066] When the dosage form of the cosmetic composition is a solution or an emulsion, a solvent, a solubilizer or an emulsifying agent can be used as the carrier ingredient, for example, water, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol oil, glycerin fatty acid ester, polyethylene glycol or sorbitol fatty acid ester.

[0067] When the dosage form of the cosmetic composition is a suspension, a liquid diluent such as water, ethanol or propylene glycol; a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester; microcrystalline cellulose; aluminum metahydroxide; bentonite; agar; or xanthan gum, etc. can be used as the carrier ingredient.

[0068] The ingredients contained in the cosmetic composition can contain, in addition to the effective ingredient and the carrier ingredient, ingredients commonly used in skin external agent composition, for example, can include antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, etc. as the conventional adjuvants.

[0069] In one embodiment, the composition can be a non-therapeutic oral composition.

[0070] In one embodiment, the daily intake of the peptide or salt thereof can be 0.0002 to 100 mg / kg (body weight). Specifically, the daily intake of the peptide or salt thereof can be 0.0002 mg / kg (body weight) or more, 0.0003 mg / kg (body weight) or more, 0.0005 mg / kg (body weight) or more, 0.0007 mg / kg (body weight) or more, 0.001 mg / kg (body weight) or more, 0.005 mg / kg (body weight) or more, 0.01 mg / kg (body weight) or more, 0.03 mg / kg (body weight) or more, 0.05 mg / kg (body weight) or more, 0.07 mg / kg (body weight) or more, 0.08 mg / kg (body weight) or more, 0.1 mg / kg (body weight) or more, 0.5 mg / kg (body weight) or more, 1 mg / kg (body weight) or more, 5 mg / kg (body weight) or more, 10 mg / kg (body weight) or more, 15 mg / kg (body weight) or more, 20 mg / kg (body weight) or more, 25 mg / kg (body weight) or more, 30 mg / kg (body weight) or more, 35 mg / kg (body weight) or more, 40 mg / kg (body weight) or more, 45 mg / kg (body weight) or more, 50 mg / kg (body weight) or more, 60 mg / kg (body weight) or more, 70 mg / kg (body weight) or more, 80 mg / kg (body weight) or more, or 90 mg / kg (body weight) or more, and in addition, the daily intake of the peptide or salt thereof can be 100 mg / kg (body weight) or less, 90 mg / kg (body weight) or less, 80 mg / kg (body weight) or less, 60 mg / kg (body weight) or less, 50 mg / kg (body weight) or less, 45 mg / kg (body weight) or less, 40 mg / kg (body weight) or less, 35 mg / kg (body weight) or less, 30 mg / kg (body weight) or less, 25 mg / kg (body weight) or less, 20 mg / kg (body weight) or less, 15 mg / kg (body weight) or less, 10 mg / kg (body weight) or less, 5 mg / kg (body weight) or less, 1 mg / kg (body weight) or less, 0.5 mg / kg (body weight) or less, 0.1 mg / kg (body weight) or less, 0.09 mg / kg (body weight) or less, 0.07 mg / kg (body weight) or less, 0.05 mg / kg (body weight) or less, 0.03 mg / kg (body weight) or less, 0.01 mg / kg (body weight) or less, 0.005 mg / kg (body weight) or less, 0.001 mg / kg (body weight) or less, 0.0007 mg / kg (body weight) or less, or 0.0005 mg / kg (body weight) or less.

[0071] In one embodiment, the dosage form of the non-therapeutic oral composition is not particularly limited, and can be, for example, tablets, granules, pills, powders, liquids such as drinks, caramels, gels, bars, tea bags, and the like. The composition of each dosage form can be, in addition to the effective ingredient, ingredients generally used in the art, which can be easily and appropriately selected and formulated by those skilled in the art depending on the dosage form or the purpose of use, and can produce a synergistic effect when applied simultaneously with other raw materials.

[0072] In one embodiment, the non-therapeutic oral composition can be administered by various methods such as simple ingestion, drinking, injection, spray, or squeeze.

[0073] In one embodiment, the non-therapeutic oral composition can be, for example, various food products such as chewing gums, chocolates, caramel products, candies, frozen dessert products, cookies, and the like, beverage products such as refreshing beverages, mineral water, alcoholic beverages, and the like, and products containing vitamins or minerals, and the like.

[0074] In one embodiment, the non-therapeutic oral composition can be directly ingested or used with other ingredients, and can be appropriately used according to conventional methods.

[0075] As one embodiment, the present application can provide the following embodiments.

[0076] The first embodiment can provide a use of a peptide including an amino acid sequence of Gly-Pro-Lys (GPK), an amino acid sequence of Gly-Pro-Ser (GPS), an amino acid sequence of Gly-Pro-Ala (GPA), an amino acid sequence of Gly-Gln-Lys (GQK), or an amino acid sequence of Pro-Hyp (PO); or a salt thereof, for preparing a composition for inhibiting hair loss or promoting hair growth.

[0077] The second embodiment can provide a use according to the first embodiment, in which the peptide is a GPK, GPS, GPA, GQK, or PO peptide.

[0078] The third embodiment can provide a use according to one or more of the first embodiment and the second embodiment, in which the peptide or the salt thereof is contained in the composition at a concentration of 0.1 to 100 μM.

[0079] The fourth embodiment can provide a use according to one or more of the first embodiment to the third embodiment, in which the peptide or the salt thereof is treated to cells at a concentration of 0.1 to 10 μM.

[0080] The fifth embodiment can provide a use according to one or more of the first embodiment to the fourth embodiment, in which the cells are hair papilla cells.

[0081] The sixth embodiment can provide a use, according to one or more of the first to fifth embodiments, wherein the peptide or salt thereof promotes or activates growth or proliferation of hair papilla cells.

[0082] The seventh embodiment can provide a use, according to one or more of the first to sixth embodiments, wherein the composition is a pharmaceutical composition for preventing or treating hair loss.

[0083] The eighth embodiment can provide a use, according to one or more of the first to seventh embodiments, wherein the daily administration amount of the peptide or salt thereof is 0.0003 to 30 mg / kg (body weight).

[0084] The ninth embodiment can provide a use, according to one or more of the first to eighth embodiments, wherein the composition is a cosmetic composition.

[0085] The tenth embodiment can provide a use, according to one or more of the first to ninth embodiments, wherein the daily application amount of the peptide or salt thereof is 0.0003 to 30 mg / kg (body weight).

[0086] The eleventh embodiment can provide a use, according to one or more of the first to tenth embodiments, wherein the composition is a non-therapeutic oral composition.

[0087] The twelfth embodiment can provide a use, according to one or more of the first to eleventh embodiments, wherein the daily intake amount of the peptide or salt thereof is 0.0003 to 30 mg / kg (body weight).

[0088] The present application is further specifically described below by way of examples. However, these examples are only for helping to understand the content of the present application, the scope of the right of the present application is not limited to these examples, and those skilled in the art can make routine known modifications, substitutions and insertions, etc., which are also included in the scope of the present application.

[0089] Example: Confirmation of the effect of activating hair papilla cell proliferation

[0090] Human dermal papilla cells (HDPCs) were seeded at 2000 cells per well in 96-well plates and cultured for 24 hours in DMEM medium (Sigma Aldrich) containing 10% FBS and 1% penicillin / streptomycin (P / S). The medium was then replaced with serum-free DMEM medium, and samples diluted with 0.1 μM, 1 μM, and 10 μM of GPK, GPS, GPA, GQK, or PO peptides were treated for 72 hours. Afterward, the samples were treated with CCK8 reagent for 1 hour. The absorbance was measured at 450 nm using a microplate reader (TECAN), and the results are shown below. Figures 1 to 5 ( Figure 1 GPK Figure 2 GPS Figure 3 GPA Figure 4 GQK Figure 5 :PO). As a positive control group (PC), the group was treated with 5% FBS (Fetal bovine serum).

[0091] from Figures 1 to 5 The results confirmed that when GPK, GPS, GPA, GQK or PO peptides were treated at concentrations of 0.1 μM, 1 μM and 10 μM, cell proliferation was significantly increased compared with the untreated control group. In particular, when treated at a concentration of 10 μM, the effect of activating dermal papilla cell proliferation was similar to that of the positive control group, thus demonstrating excellent results.

Claims

1. Use of a peptide comprising the amino acid sequence of Gly-Pro-Lys, the amino acid sequence of Gly-Pro-Ser, the amino acid sequence of Gly-Pro-Ala, the amino acid sequence of Gly-Gln-Lys, or the amino acid sequence of Pro-Hyp, for preparing compositions for inhibiting hair loss or promoting hair growth; or the use of a salt thereof.

2. The use according to claim 1, wherein, The peptide is GPK, GPS, GPA, GQK, or PO peptide.

3. The use according to claim 1, wherein, The composition contains the peptide or its salt at a concentration of 0.001 to 100 μM.

4. The use according to claim 1, wherein, The peptide or its salt is treated into cells at a concentration of 0.1 to 10 μM.

5. The use according to claim 4, wherein, The cells in question are dermal papilla cells.

6. The use according to claim 1, wherein, The peptide or its salt promotes or activates the growth or proliferation of dermal papilla cells.

7. The use according to claim 1, wherein, The composition is a pharmaceutical composition for the prevention or treatment of hair loss.

8. The use according to claim 7, wherein, The daily dose of the peptide or its salt is 0.0003 to 30 mg / kg body weight.

9. The use according to claim 1, wherein, The composition is a cosmetic composition.

10. The use according to claim 9, wherein, The daily dose of the peptide or its salt is 0.0003 to 30 mg / kg body weight.

11. The use according to claim 1, wherein, The composition is a non-therapeutic oral composition.

12. The use according to claim 11, wherein, The daily intake of the peptide or its salt is 0.0003 to 30 mg / kg body weight.

Images